Zacks Investment Research on MSN12d
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?Novo Nordisk NVO shares have lost 15.2% so far this month compared with the industry’s decline of 4.6%. The company has also ...
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April ...
Meitheal Pharmaceuticals recently launched two new generics. The company released alprostadil injection 500 mcg/ml single-dose vials to the U.S. market, where only an ampoule form is offered. The ...
Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by ...
Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...
Dividends and the share repurchase programs of the Novo Group companies (Novo Nordisk and Novonesis) totaled 23 billion Danish kroner, and Returns from the Investment Portfolio generated an income ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback